This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to RRP over the long term.

This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness. 

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients.

This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients.

This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients.

This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher rate of tumor recurrence. 

This study evaluated the safety of eliminating routine postoperative blood tests after conducting robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer (PCa) and proposed recommendations for their use. 

This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients.

The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide.